Showing results (101-110 of 299) with videos related to
Sort By:
Pageof 30
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|July 27, 2017
Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?Wafik S El-Deiry, Barry Taylor, Joel W NealJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 21, 2023
Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic AgentsBrianna C Lau, Yufan F Wu, Hyunsoo J No, et al.JAMA Network Open|November 15, 2023
Second Primary Lung Cancer Among Lung Cancer Survivors Who Never SmokedEunji Choi, Chloe C Su, Julie T Wu, et al.JTO Clinical and Research Reports|March 14, 2022
Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLCJohn M Varlotto, Yating Wang, Zhuoxin Sun, et al.Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancerJeremy P Harris, Manali I Patel, Billy W Loo, et al.Lung India : Official Organ of Indian Chest Society|July 18, 2022
A brief report on the mutational landscape in non-small cell lung cancer of South Asian patients: Comparison at a US and an Indian InstitutionMohana Roy, Amanjit Bal, Nalini Gupta, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, et al.The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.Frontiers in Oncology|April 10, 2023
Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI stagingSaud Alhusaini, Tyler A Lanman, Ryan B Ko, et al.Lung Cancer (Amsterdam, Netherlands)|February 10, 2026
Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trialsYating Wang, Zhuoxin Sun, Arthi Sridhar, et al.Pageof 30